{"schema_version":"secwatch.filing_event.v1","accession":"0001388658-24-000096","form_type":"8-K","ticker":"IRTC","cik":"0001388658","company_name":"iRhythm Holdings, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.193618+00:00","generated_at":"2026-06-03T00:14:23.542481+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"iRhythm Q1 revenue $131.9M (+18.4% YoY); net loss widens to $45.7M; raises FY revenue guidance to $578-588M","bullets":["Revenue $131.9M (+18.4% YoY); gross margin 66.3% (down 160 bps YoY).","Net loss $45.7M ($1.47/share) vs $39.1M ($1.29) YoY; adjusted loss $38.1M ($1.23) vs $33.4M ($1.10).","FY2024 revenue guidance raised to $578-588M (17-19% growth); gross margin 68-69%, adj. EBITDA margin 3-4%.","Over 500K registrations in Q1; announced Epic Aura collaboration for EMR integration; heart failure prediction data presented at ACC.","Unrestricted cash, equivalents, and marketable securities $569.1M as of March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001388658-24-000096","json":"https://secwatch.observer/filing/0001388658-24-000096.json","markdown":"https://secwatch.observer/filing/0001388658-24-000096.md","text":"https://secwatch.observer/filing/0001388658-24-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388658/000138865824000096/0001388658-24-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388658/000138865824000096/irtc-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:14:23.542481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6675d1634bf24ae6357a3dabfc257da0a78503e","claim":"iRhythm Holdings, Inc. reported three months ended March 31, 2024 results: revenue $131.9 million, net income $45.7 million, or a diluted loss of $1.47 per share, EPS $1.47 per share. Guidance raised.","evidence_excerpt":"that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights • Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023 • Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023 • Unrestricted cash, cash equivalents and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388658/000138865824000096/0001388658-24-000096-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$131.9 million"},{"label":"Net income","value":"$45.7 million, or a diluted loss of $1.47 per share"},{"label":"EPS","value":"$1.47 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}